Ultrasound Guided Fine-Needle Aspiration Biopsy Proves 100% Accurate in 166 Women

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

A study of 166 women with suspicious mammograms who underwent ultrasound-guided fine-needle aspiration cytology (USFNAC) showed the technique to be 100% accurate in diagnosing cancers, reported Dr. Thomas G. Frazier at the annual

A study of 166 women with suspicious mammograms who underwentultrasound-guided fine-needle aspiration cytology (USFNAC) showedthe technique to be 100% accurate in diagnosing cancers, reportedDr. Thomas G. Frazier at the annual meeting of the American RadiumSociety, held in Paris, France. This number is based on 3-monthfollow-up of the patients, said Dr. Frazier, who is Senior AttendingSurgeon at the Bryn Mawr Hospital in Bryn Mawr, Pennsylvania,

"We found 17 early cancers in our study (none could be felt),"said Dr. Frazier, who is also Clinical Professor of Surgery atthe Medical College of Pennsylvania. "In our study, the costto diagnose each cancer was $4,667 when USFNAC was used. Thiscompares to $52,505 per cancer diagnosed for standard biopsy procedures.That's more than a 91% savings," he commented.

"We looked at the costs of biopsy alone by averaging thecosts of five patients and found that standard biopsies cost about$5,377. This compares to USFNAC, which costs only $478 per procedure,"he said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content